752 related articles for article (PubMed ID: 27712712)
1. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
[TBL] [Abstract][Full Text] [Related]
2. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
Lloyd AJ; Kerr C; Penton J; Knerer G
Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
[TBL] [Abstract][Full Text] [Related]
3. "The validity of the EQ-5D-5L in measuring quality of life benefits of breast reconstruction".
Kouwenberg CAE; Kranenburg LW; Visser MS; Busschbach JJ; Mureau MAM
J Plast Reconstr Aesthet Surg; 2019 Jan; 72(1):52-61. PubMed ID: 30270015
[TBL] [Abstract][Full Text] [Related]
4. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martà Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
5. The EQ-5D-5L Is Superior to the -3L Version in Measuring Health-related Quality of Life in Patients Awaiting THA or TKA.
Jin X; Al Sayah F; Ohinmaa A; Marshall DA; Smith C; Johnson JA
Clin Orthop Relat Res; 2019 Jul; 477(7):1632-1644. PubMed ID: 30801280
[TBL] [Abstract][Full Text] [Related]
6. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L.
Lorgelly PK; Doble B; Rowen D; Brazier J;
Qual Life Res; 2017 May; 26(5):1163-1176. PubMed ID: 27830513
[TBL] [Abstract][Full Text] [Related]
7. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
[TBL] [Abstract][Full Text] [Related]
9. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
[TBL] [Abstract][Full Text] [Related]
10. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.
Rowen D; Young T; Brazier J; Gaugris S
Value Health; 2012 Dec; 15(8):1059-68. PubMed ID: 23244808
[TBL] [Abstract][Full Text] [Related]
11. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
12. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
[TBL] [Abstract][Full Text] [Related]
13. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
[TBL] [Abstract][Full Text] [Related]
14. Construct Validity of the EuroQoL-5 Dimension and the Health Utilities Index in Head and Neck Cancer.
Noel CW; Keshavarzi S; Forner D; Stephens RF; Watson E; Monteiro E; Hosni A; Hansen A; Goldstein DP; de Almeida JR
Otolaryngol Head Neck Surg; 2022 May; 166(5):877-885. PubMed ID: 34311628
[TBL] [Abstract][Full Text] [Related]
15. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
16. Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L.
Herdman M; Kerr C; Pavesi M; Garside J; Lloyd A; Cubi-Molla P; Devlin N
J Patient Rep Outcomes; 2020 Mar; 4(1):22. PubMed ID: 32219576
[TBL] [Abstract][Full Text] [Related]
17. Comparison of EQ-5D-5L and SPVU-5D for measuring quality of life in patients with venous leg ulcers in an Australian setting.
Cheng Q; Kularatna S; Lee XJ; Graves N; Pacella RE
Qual Life Res; 2019 Jul; 28(7):1903-1911. PubMed ID: 30778889
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
19. Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France.
Wojciechowski P; Wdowiak M; Hakimi Z; Wilson K; Fishman J; Nazir J; Toumi M
J Comp Eff Res; 2023 May; 12(5):e220178. PubMed ID: 37052120
[No Abstract] [Full Text] [Related]
20. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
